EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Application of experimental design in optimization of solid phase extraction of mycophenolic acid and mycophenolic acid glucuronide from human urine and plasma and SPE-RP-HPLC method validation



Application of experimental design in optimization of solid phase extraction of mycophenolic acid and mycophenolic acid glucuronide from human urine and plasma and SPE-RP-HPLC method validation



Journal of Pharmaceutical and Biomedical Analysis 47(3): 575-585



The aim of this study was to develop and optimize a solid phase extraction (SPE) procedure for purification of mycophenolic acid (MPA) and its metabolite mycophenolic acid glucuronide (MPAG) in biological samples. During optimization process chemometric approach was applied. First, in screening experiments fractional factorial design (FFD) was used for selecting the variables which affected the extraction procedure. The ionic strength of the phosphate buffer in the washing step and the percentage of acetonitrile in the elution step were statistically significant for the recovery of MPAG while the percentage of acetonitrile and pH of the washing solution were statistically significant for that of MPA. Afterwards, the significant variables were optimized using central composite design (CCD). The developed SPE method included phosphate buffer (pH 2.4; 0.056 M) in the washing step, and the mixture of acetonitrile and phosphate buffer of which pH was adjusted to 2.4 (70:30, v/v) in the elution step. The investigation was applied to both urine and plasma and the nature of biological matrix appeared to be of no importance. The extraction from both matrixes showed good repeatability with relative standard deviations up to 6% for MPAG and 8% for MPA, and recovery around 100% for both substances. Furthermore, new SPE-RP-HPLC method for determination of MPA and MPAG in both humane urine and plasma has been validated. The great advantage of this method is the chromatographic run of only 3 min.

(PDF emailed within 0-6 h: $19.90)

Accession: 030151332

Download citation: RISBibTeXText

PMID: 18356001

DOI: 10.1016/j.jpba.2008.01.046



Related references

A high-throughput U-HPLC-MS/MS assay for the quantification of mycophenolic acid and its major metabolites mycophenolic acid glucuronide and mycophenolic acid acyl-glucuronide in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 883-884: 113-119, 2012

New Solid Phase Extraction Method for Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Plasma. Therapeutic Drug Monitoring 27(2): 215-216, 2005

Multicriteria optimization methodology in development of HPLC separation of mycophenolic acid and mycophenolic acid glucuronide in human urine and plasma. Journal of Pharmaceutical and Biomedical Analysis 50(4): 640-648, 2008

A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Therapeutic Drug Monitoring 21(3): 322-324, 1999

HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. Journal of Pharmaceutical and Biomedical Analysis 36(3): 649-651, 2004

High-performance liquid chromatography method for the determination of mycophenolic acid in human plasma and application to a pharmacokinetic study of mycophenolic acid dispersible tablet. Arzneimittel-Forschung 58(7): 348-352, 2008

Determination of lipoic acid in human plasma by HPLC-ECD using liquid-liquid and solid-phase extraction: Method development, validation and optimization of experimental parameters. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 878(28): 2782-2788, 2011

Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 859(1): 42-51, 2007

Determination of mycophenolic acid (MPA) and its acyl and phenol glucuronide metabolits simultaneously in human plasma by a simplified HPLC method. Analytical Letters 40(13): 2465-2475, 2007

Stability of mycophenolic acid and mycophenolic acid glucuronide in human plasma. Clinical Chemistry 45(1): 127-129, 1999

Simple reversed-phase ion-pair liquid chromatography assay for the simultaneous determination of mycophenolic acid and its glucuronide metabolite in human plasma and urine. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 805(1): 101-112, 2004

Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 844(1): 142-147, 2006

The inhibition of human inosine monophosphate dehydrogenase by mycophenolic acid glucuronide is due to the presence of trace quantities of mycophenolic acid. Clinical Chemistry 44(6 PART 2): A101, June, 1998

Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clinical Chemistry 46(3): 365-372, 2000

Fully automated analytical method for mycophenolic acid quantification in human plasma using on-line solid phase extraction and high performance liquid chromatography with diode array detection. Therapeutic Drug Monitoring 28(4): 505-511, 2006